Abstract
Hydrogels have played a vital role in the development of controlled-release drug delivery systems. A hydrogel (also called an aquagel) is a three-dimensional (3-D) network of hydrophilic polymers swollen in water (1). The 3-D polymer network of a hydrogel is maintained in the form of elastic solid in the sense that there exists a remembered reference configuration to which the system returns even after being deformed for a very long time. By definition, hydrogels usually contain water at least 10% of the total weight. The term hydrogel implies that the material is already swollen in water. Dried hydrogels (or xerogels) absorb water to swell, and the size of the swollen gel depends on how much water is absorbed. A hydrogel swells for the same reason that an analogous linear polymer dissolves in water to form an ordinary polymer solution. The extent of swelling is usually measured by the swelling ratio, which is the volume (or weight) of the swollen gel divided by the volume (or weight) of the xerogel. If the weight of absorbed water exceeds 95% of the total weight, a hydrogel is often called a superabsorbent. Thus, 20g of fully swollen superabsorbent will have 1g or less of polymer network and 19g or more of water (i.e., the swelling ratio is more than 20). The swelling ratio of many hydrogels can easily reach greater than 100. Despite such a large quantity of water, highly swollen hydrogels still maintain solid forms.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Park K, Shalaby SWS, Park H. Biodegradable Hydrogels for Drug Delivery Technomic, Lancaster, PA. 1993, Ch. 1.
Akiyoshi K, Taniguchi I, Fukui H, Sunamoto J. Hydrogel nanoparticle formed by self-assembly or hydrophobized polysaccharide: stabilization of adriamycin by complexation. Eur J Pharm Biopharm 1996; 42:286–290.
Akiyoshi K, Deguchi S, Tajima H, Nishikawa 1, Sunamoto J. microscopic structure ana mermoresponsiveness of a hydrogel nanoparticle by self-assembly of a hydrophobized polysaccharide, Macromolecules 1997; 30:857–861. 11.
Narayani R, Panduranga Rao K. Collagen-poly (EMA) hydrogeis ror thie controlled uenvery w methotrexate and cisplatin, Int J Pharm 1996; 138:121–124.
Blanco MD, Trigo RM, Garcia O, Teijon JM. Controlled release or cytarabine from poly(2-hyuroAyethyl methacrylate-co-n-vinyl-2-pyrrolidone) hydrogels, J Biomater Sci Polymer Edn 1997; 8:709–719.
Teijon JM, Trigo RM, Garcia O, Blanco MD. Cytarabine trapping in poly(2-hydroxyetnyi metnacrylate) hydrogels-drug delivery studies, Biomaterials 1997; 18:383–388.
Beyssac E, Bregni C, Aiache JM, Gerula S, Smolko E. Hydrogel implants for methotrexate obtained by ionizing radiation, Drug Devel Ind Pharm 1996; 22:439 414.
Garcia O, Trigo RM, Blanco MD, leijon JM. influence of aegree of crossimung on 5-uoiuuraii release from poly(2-hydroxyethyl methacrylate) hydrogels, Biomaterials 1994; 15:689–694.
Trigo RM, Blanco MD, Teijon JM, Sastre R. Anticancer drug, ara-C, release from pHEMA hydrogels, Biomaterials 1994; 15:1181–1186.
Blanco MD, Garcia O, Trigo RM, Teijon JM, Katime I. 5-Fluorouracil release from copolymeric hydrogels of itaconic acid monoester, Biomaterials 1996; 17:1061–1067.
Blanco MD, Garcia O, Olmo R, Teijon JM, Katime 1. elease of 5-nuorouraeilfro ply (cr yiauueco-monopropyl itaconate) hydrogels, J Chromatogr B: Biomed Appl 1996; 680:243–253.
Chen J, Park H, Park K. Synthesis of superporous hydrogels: hydrogels with fast swelling and superabsorbent properties, J Biomed Mater Res 1999; 44:53–62.
Kato T. Encapsulated drugs in targeted cancer therapy, in Controllea Drug Delivery. vol. II. tnicat Applications (Bruck SD, ed). CRC, Boca Raton, FL, 1983, pp 189–240.
Lindberg B, Lote K, Teder H. Dioderadable starch microspheres-A new medical tool, in microspheres and Drug Therapy-Pharmaceutical, Immunological and Medical Aspects (Davis SS, Illum L, McVie JG, Tomlinson E, eds). Elsevier, New York, 1983, pp 153–188.
Horak D, Svec F, Adamyan A, et al. Hydrogels in endovascular embolization. V. Antitumour agent methotrexate-containing p(HEMA), Biomaterials 1992; 13:361–366.
Fiorentini G, Campanini A, Dazzi C, et al. Chemoembolization in liver malignant involvement. txperiences on 17 cases, Minerva Chirurgica 1994; 49:281–285.
Päuser S, Wagner S, Lippman M, et al. Evaluation of efficient chemoembolization mixtures by magnetic resonance imaging therapy monitoring: An experimental study on the VX2 tumor in the rabbit liver, Cancer Res 1996; 56:1863–1867.
Colleoni M, Audisio RA, De Braud F, Fazio N, Martinelli G, Goldhirsch, A. Practical considerations in the treatment of hepatocellular carcinoma, Drugs 1998; 55:367–382.
Taguchi T. Liver tumor targeting of drugs: Spherex, a vascular occlusive agent, Jap J Cancer & Chemotherapy 1995; 22:969–976.
Tellez C, Benson AB, Lyster MT, et al. Phase II trial of chemoembolization for the treatment or metastatic colorectal carcinoma to the Liver and review of the literature, Cancer 1998; 82:1250–1259. .
Kyotani S, Nishioka Y, Okamura M, et al. A study of embolizing materials for chemo-embolization therapy of hepatocellular carcinoma: antitumor effect of cis-diamminedichloroplatinum(II) albumin microspheres, containing chitin and treated with chitosan on rabbits with VX2 hepatic tumors, Chem Pharmaceut Bull 1992; 40:2814–2816.
Teder H, Johansson CJ. The effect of different dosages of degradable starch microspheres (Spherex) on the distribution of doxorubicin regionally administered to the rat, Anticancer Res 1993; 13:2161–2164.
Chang D, Jenkins SA, Grime SJ, Nott DM, Cooke T. Increasing hepatic arterial flow to hypovascular hepatic tumours using degradable starch microspheres, Br J Cancer 1996; 73:961–965.
Horak D, Svec F, Isakov Y, et al. Use of poly(2-hydroxyethyl methacrylate) for endovascular occlusion in pediatric surgery, Clin Mater 1992; 9:43–48.
Begg AC, Deurloo MJ, Kop W, Bartelink H. Improvement of combined modality therapy with cisplatin and radiation using intratumoral drug administration in murine tumors, Radiother Oncol 1994; 31:129–137.
Deurloo MJ, Kop W, van Tellingen O, Bartelink H, Begg AC. Intratumoural administration of cisplatin in slow-release devices: II. Pharmacokinetics and intratumoural distribution, Cancer Chemother Pharmacol 1991; 27:347–353.
Deurloo MJ, Bohlken S, Kop W, et al. Intratumoural administration of cisplatin in slow-release devices. I. Tumour response and toxicity, Cancer Chemotherapy & Pharmacology 1990; 27:135–140.
Park KB, Kim YM, Kim JR. Radioactive chitosan complex for radiation therapy. U.S. Patent 1998; 5:762,903.
Suzuki Y, Momose Y, Higashi N, et al. Biodistribution and kinetics of Holmium-166-chitosan complex (DW-166HC) in rats and mice, J Nucl Med 1998; 39:2161–2166.
Chiellini E, Solaro R, Leonardi G, Giannasi D, Mazzanti G. New polymeric hydrogel formulations for the controlled release of alpha-interferon, J Controlled Rel 1992: 22:273–282.
Veronese FM, Ceriotti G, Keller G, Lora S, Carenza M. Controlled release of narciclasine from poly(hema) matrices polymerized by a chemical initiator and by gamma irradiation, Radiation Physics & Chemistry 1990; 1990:88–92.
Veronese FM, Ceriotti G, Caliceti P, Lora S, Carenza M. Slow release of narciclasine from matrices obtained by radiation-induced polymerization, J Controlled Rel 1991; 16:291–298.
Giammona G, Pitarresi G, Tomarchio V, Cavallaro G, Mineo M. Crosslinked alpha, beta-polyasparthydrazide hydrogels: effect of crosslinking degree and loading method on cytarabine release rate, J Controlled Rel 1996; 41:195–203.
Jeyanthi R, Panduranga Rao K. In vivo biocompatibility of collagen-poly(hydroxyethyl methacrylate) hydrogels, Biomaterials 1990; 11:238–243.
Jeyanthi R, Panduranga Rao K. Controlled release of anticancer drugs from collagen-poly(HEMA) hydrogel matrices, J Controlled Rel 1990; 13:91–98.
Jeyanthi R, Panduranga Rao K. Equilibrium swelling behavior of collagen-poly (HEMA) copolymeric hydrogels, J App Polymer Sci 1991; 43:2332–2336.
Uemura K, Kurono Y, Ikeda K. Application of implantable collagen-poly (hydroxyethyl methacrylate) hydrogels containing camptothecin derivative to solid tumor chemotherapy, Jpn J Hosp Pharm Byoin Yakugaku 1994; 20:33–40.
Jeyanthi R, Nagarajan B, Panduranga Rao, K. Solid tumor chemotherapy using implantable collagenpoly(HEMA) hydrogel containing 5-fluorouracil, J Pharm Pharmacol 1991; 43:60–62.
Ulbrich K, Subr V, Seymour LW, Duncan R. Novel biodegradable hydrogels prepared using the divinylic crosslinking agent N,O-dimethacryloylhydroxylamine. Part 1. Synthesis and characterization of rates of gel degradation, and rate of release of model drugs, in vitro and in vivo, J Controlled Rel 1993; 24:181–190.
Ulbrich K, Subr V, Podperova P, Buresova M. Synthesis of novel hydrolytically degradable hydrogels for controlled drug release, J Controlled Rel 1995; 34:155–165.
Weissleder R, Bogdanov A, Frank H, et al. AUR Memorial Award 1993. A drug system (PDH) for interventional radiology. Synthesis, properties, and efficacy, Investigative Radiology 1993; 28:1083–1089.
Weissleder R, Poss K, Wilkinson R, Zhou C, Bogdanov A, Jr. Quantitation of slow drug release from an implantable and degradable gentamicin conjugate by in vivo magnetic resonance imaging, Antimicrobial Agents & Chemoth 1995; 39:839–845.
Giammona G, Pitarresi G, Carlisi B, Cavallaro G. Crosslinked alpha, beta-polyasparthydrazide micromatrices for controlled release of anticancer drugs, J Bioact Compat Polymers 1995; 10:28–40.
Giammona G, Carlisi B, Cavallaro G, Pitarresi G, Spampinato S. A new water-soluble synthetic polymer, alpha, beta -polyasparthydrazide, as poential plasm expander and drug carrier, J Controlled Rel 1994; 29:63–72.
Ravichandran P, Shantha KL, Rao KP. Preparation, swelling characteristics and evaluation of hydrogels for stomach specific drug delivery, Int J Pharm 1997; 154:89–94.
Yamini C, Shantha KL, Rao KP. Synthesis and characterization of po1y[n-viny1–2-pyrro1idone-po1yethylene glycol diacrylate] copolymeric hydrogels for drug delivery, J Macromol Sci Pure Appl Chem A34 1997; 12:2461–2470.
Dolz M, Gonzalez F, Herraez M, Diez O. Influence of polymer concentration on tne 5-nuorouracii release rate from Carbopol hydrogels, J Pharmacie de Belgique 1994; 49:509–513.
Dolz M, Rodriguez FG, Dominguez MH. The influence ot neutralizer concentration on me rheologicaa behavior of a 0.1% Carbopol hydrogel, Pharmazie 1992; 47:351–355.
Gelliarth KA, DeSantis P. A brief review of the pathophysiology and treatment of cutaneous i-cell lymphoma “mycosis fungoides”, Ostomy Wound Manag 1995; 41:44–48.
Gross G, Roussaki A, Pfister H. Postoperative interferon hydrogel treatment. A method tor the successful therapy of chronic persistent giant condylomas in an immunologically deficient patient with Hodgkin’s disease, Hautarzt 1988; 39:684–687.
Fierlbeck G, Rassner G, Pfister H. Condylomata acuminata in children-detection ot V b/11 ana 2. Local therapy with interferon-beta hydrogel, Hautarzt 1992; 43:148–151.
Umejima H, Kikuchi A, Kim NS, Uchida T, Goto S. Preparation and evaluation ot Eucragit gels. v Rectal absorption of 5-fluorouracil from Eudispert hv gels in rats, J Pharm Sci 1995; 84:199–202.
Okada N, Fushimi M, Nagata Y, et al. A quantative in vivo method of analyzing human tumor-induced angiogenesis in mice using agarose microencapsulation and hemoglobin enzyme-linked immunosorbent assay, Jap J Cancer Res 1995; 86:1182–1188.
Okada N, Kaneda Y, Miyamoto H, et al. Selective enhancement by tumor necrosis tactor-alpha ot vascular permeability of new blood vessels induced with agarose hydrogel-entrapped Meth-A fibrosarcoma cells, Jap J Cancer Res 1996; 87:831–836.
Winchester JF, Rahman A, Tilstone WJ, Kessler A, Mortensen L, Schreiner (E, Schein S. sorbent removal of adriamycin in vitro and in vivo, Cancer Treatment Rep 1979; 63:1787–1793.
Plate NA, Valuev LI, Valueva TA, Chupov VV. Biospecific haemosorbents based on proteinase inhibitor. I. Synthesis and properties, Biomaterials 1993; 14:51–56.
Plate NA, Valuev LI. Affinity chemotherapy and diagnostics using some novel polymeric nydrogeis, Polymers Adv Technol 1994; 5:634–644.
Tracey KJ, Mutkoski R, Lopez JA, Franzblau W, Franzblau C. Radioimmunoassay tor methotrexate using hydroxyethylmethacrylate hydrogel, Cancer Chemother Pharmacol 1983; 10:96–99.
Lawrence RM, Hoeprich PD. Totally synthetic medium tor susceptibility testing, Anumicrobiat Agents Chemother 1978; 13:394–398.
Teicher, BA. Antiangiogenic Agents in Cancer Therapy Humana Press, Totowa, NJ, 1999.
Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vascuarture in a mouse model, Science 1998; 279:377–380.
Wichterle O, Lim D. Hydrophilic gels for biological use, Nature 1960; 185:117–118.
Park K, Park H. Smart hydrogels, in Concise Polymeric Materials Encyctopeaia (Saanione CD). CRC, Boca Raton, FL, 1999, pp 1476–1478.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer Science+Business Media New York
About this chapter
Cite this chapter
Hwang, SJ., Baek, N., Park, H., Park, K. (2004). Hydrogels in Cancer Drug Delivery Systems. In: Brown, D.M. (eds) Drug Delivery Systems in Cancer Therapy. Cancer Drug Discovery and Development. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-427-6_5
Download citation
DOI: https://doi.org/10.1007/978-1-59259-427-6_5
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61737-238-4
Online ISBN: 978-1-59259-427-6
eBook Packages: Springer Book Archive